Unrecognized post-operative residual neuromuscular block remains a frequent occurrence in todays’ recovery rooms. Evidence indicates that current practice continues to perpetuate the status quo, in which 10-40% of patients experience postoperative residual weakness.
The use of muscle relaxants calls for quantitative objective monitoring
There is a strong consensus that quantitative objective monitoring of neuromuscular function should be used when non-depolarizing neuromuscular blocking agents (NMBA) are administered (Naguib et al., 2017).